The chief executive of AstraZeneca, which is developing a leading coronavirus vaccine with Oxford University, said it is too early to deliberately expose trial participants to the pathogen, but it may become an option if ongoing tests hit a snag.
As some U.S. states look to start reopening their coronavirus-battered economies amid protests from supporters of President Donald Trump anxious to get back to work, hardest hit New York state began mandating the wearing of masks or face coverings in public to contain the pathogen’s spread.
The U.S. Department of Health and Human Services is partnering with Regeneron Pharmaceuticals Inc. to develop a treatment for the coronavirus, making the drugmaker the latest to join the race to develop a therapy.
Shionogi & Co. Ltd. announced results from APEKS-NP, an international, double-blind, randomized Phase III clinical trial evaluating the efficacy and safety of the investigational antibiotic cefiderocol in patients with nosocomial pneumonia (NP).
Researchers with Cortexyme published research in the journal Science Advances describing the role of Porphyromonas gingivalis, a bacteria that causes gingivitis, to Alzheimer’s disease.
Drugmakers’ response to the threat posed by “superbugs” remains patchy even after years of warnings, according to the first analysis of individual companies’ efforts to tackle the antibiotic resistance crisis.
AvidBiotics is splitting into two separate companies. AvidBiotics developed two separate but similar technology platforms, which will be the foundation for the two companies. Both companies’ technology utilize proteins that attack specific cells. One platform focuses on cancer cells while the other focuses on bacteria.
New antibiotics need to be developed urgently to combat 12 bacteria families, “priority pathogens” that are the greatest threats to human health, WHO says.
A sign explaining the parameters concerning the Zika virus and blood donations is seen at the American Red Cross Charles Drew Donation Center in Washington February 16, 2016. Reuters/Gary Cameron The U.S. government said on Monday it has agreed to help fund two pathogen reduction technologies to help reduce the risk of Zika virus and […]
KALAMAZOO, Mich., Feb. 24, 2016 /PRNewswire/ — AureoGen Biosciences Inc. today announced a licensing agreement with Merck, known as MSD outside the United States and Canada, for the use of AureoGen’s proprietary chemistry and compounds for the development of medicines for infectious disease, including systemic fungal infections. Under the agreement, Merck receives exclusive rights to […]